Gilead's New CEO Is Going All-In on Acquisitions

Jason Hawthorne, The Motley Fool
·6-min read
Gilead's New CEO Is Going All-In on Acquisitions

Daniel O'Day has made increasingly larger deals in an effort to improve the company's portfolio of cancer drugs.